News for Personalis, Inc. (PSNL)

Personalis, Inc. (PSNL) grants a stock option to its new VP under Nasdaq Listing Rule 5635(c)(4). The stock option covers 100,000 shares with a vesting

[url="]Personalis, Inc.[/url] (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Boar

PR NewswireVANCOUVER, BC, July 16, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, July 16, 2025 /PRNewswire/

Personalis Inc. (PSNL) expands its strategy by enhancing its collaboration with Tempus AI. Analysts predict significant movements with target prices ran

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.

[url="]Personalis, Inc.[/url] (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), addi

Personalis offers promising ultra-sensitive MRD genomic tests, but faces intense competition that threatens growth and profitability. See why PSNL stock is a Hold.

[url="]Personalis, Inc[/url]. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA ph

Personalis (PSNL) has unveiled significant findings from its CALLA phase 3 study, revealing that the NeXT Personal circulating tumor DNA blood test can detect t

Personalis, Inc.

Personalis (PSNL) has unveiled promising findings from its PREDICT DNA and SCANDARE studies, emphasizing the effectiveness of its NeXT Personal ctDNA blood test

[url="]Personalis, Inc[/url]. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of

Personalis, Inc. (PSNL) to present latest data at ASCO Annual Meeting in Chicago, Illinois. Presentations focus on NeXT Personal® ultrasensitive ctDNA

Life Science & Diagnostic Tools Analyst, Massaro, is set to engage with the management team of a company via a virtual meeting scheduled for December 8. This ev

Guggenheim has begun its analysis of Personalis (PSNL), issuing a Buy rating and setting a price target of $6 for the stock. This move indicates Guggenheim's po

ARK ETFs sold 376,874 Palantir (PLTR) shares for $46.65 million, continuing a week-long reduction, while investing $10.45 million in 237,374 Guardant Health (GH) shares, signaling a shift from data analytics to precision oncology. Significant purchases included $10.17 million for 283,186 Twist Bioscience (TWST) shares and $8.75 million for 55,623 Natera…

On May 7, 2025, a notable development was reported regarding Personalis (PSNL). The well-regarded financial services firm, HC Wainwright & Co., has maintained i

H.C. Wainwright has revised its price target for Personalis (PSNL), boosting it from $8 to $9, while maintaining a Buy rating on the stock. This decision comes

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPSNL.OQ - Personalis IncQ1 2025 Personalis Inc Earnings CallMay 06, 2025 / 09:00PM GMT =======